Pear Bio logo

Pear Bio

Patient-centered cancer precision medicine

10 employees · est. 2017 · London, United Kingdom

VS
Vevo Therapeutics logo

Vevo Therapeutics

We are combining in vivo data and AI to find better targets and drugs that can treat more patients.

25 employees · est. 2022

Pear Bio is the older company (2017 vs 2022); Vevo Therapeutics is the larger of the two.

Side-by-Side Comparison

Pear Bio Vevo Therapeutics
Founded
2017 older 2022
Headquarters
London, United Kingdom Not tracked yet
Employees
10 25 larger
Industry
Biotechnology, Health Care AI, Biotechnology, Health and Wellness
Funding Stage
Series A Seed
Total Funding
$19.79M $12.00M
Funding Rounds
9 1
Services
Personalized Testing Services, Drug Discovery Not tracked yet
Target Customers
Cancer Patients, Oncologists, Biopharmaceutical Companies, Medical Researchers Not tracked yet
Taxonomy
Precision Medicine, Cancer Biology, Functional Genomics, 3D Microtumor Platforms, Computational Biology, Drug Discovery, Biomarker Development, AI In Oncology, Ex Vivo Testing, Multi-omics, Immune-Microtumors, Patient-Centric Therapies, Image-Based Biomarkers, 3D Computer Vision, Therapeutic Development In Vivo Data, Drug Discovery, Mosaic Platform, Single-cell Precision, Patient Diversity, In Vivo Atlas, Genomics, Computational Biology, Chemistry, San Francisco, Investors, Life Sciences, Technology
Website
pearbio.com vevo.ai
Pear Bio logo

About Pear Bio

Pear Bio, founded in 2017 and headquartered in the United Kingdom, is making strides in the fields of Biotechnology and Health Care with its focus on Patient-centered cancer precision medicine. The company employs a proprietary computational biology platform to unravel intricate cancer biology, faci...

Vevo Therapeutics logo

About Vevo Therapeutics

Vevo Therapeutics is a biotechnology startup founded in 2022, with a mission to revolutionize drug discovery using in vivo data and AI. The company's Mosaic platform is pioneering in capturing in vivo context of diseases with single-cell precision, enabling a more accurate representation of patient...

We will tell you when either one moves

BounceWatch watches Pear Bio and Vevo Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Pear Bio and Vevo Therapeutics — by email.

Frequently Asked Questions

Pear Bio — Patient-centered cancer precision medicine. Vevo Therapeutics — We are combining in vivo data and AI to find better targets and drugs that can treat more patients.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Pear Bio has raised $19.79M while Vevo Therapeutics has raised $12.00M.
Pear Bio and Vevo Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Pear Bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Pear Bio on 15 Jun 2026, and Vevo Therapeutics on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy